<DOC>
	<DOCNO>NCT00118196</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , azacitidine arsenic trioxide , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase II trial study well give azacitidine together arsenic trioxide work treat patient myelodysplastic syndrome chronic myelomonocytic leukemia .</brief_summary>
	<brief_title>Azacitidine Arsenic Trioxide Treating Patients With Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient myelodysplastic syndrome chronic myelomonocytic leukemia treat azacitidine arsenic trioxide . Secondary - Determine time treatment failure patient treat regimen . - Determine tolerability toxicity regimen patient . - Determine progression-free survival patient treat regimen . OUTLINE : This multicenter , non-randomized , open-label , study . Patients receive azacitidine subcutaneously daily day 1-5 arsenic trioxide IV 1-2 hour day 1 , 2 , 8 , 9 , 15 , 16 , 22 , 23 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . Patients evaluated response day 113 ( week 17 ) . Patients disease progression response remove study . Patients achieve complete response ( CR ) receive 2 additional course therapy undergo observation . Patients achieve partial response receive 2 additional course therapy receive arsenic trioxide alone twice weekly absence CR , disease progression , unacceptable toxicity . After completion study treatment , patient follow every 2 month least 1 year . PROJECTED ACCRUAL : A total 19-41 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis myelodysplastic syndrome chronic myelomonocytic leukemia International Prognostic Scoring System ( IPSS ) score ≥ intermediate1 Low IPSS score allow provided patient meet ≥ 1 follow criterion : Platelet count ≤ 50,000/mm^3 Required platelet pack red cell transfusion within past 4 week Neutropenic ( i.e. , absolute neutrophil count &lt; 1,000/mm^3 ) AND infection require antibiotic treatment No prior leukemia refractory anemia excess blast transformation PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy More 12 week Hematopoietic See Disease Characteristics Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Renal Creatinine ≤ 1.5 time ULN Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Baseline QTc &lt; 500 msec QTc interval &lt; 460 msec potassium &gt; 4.0 mEq/L magnesium &gt; 1.8 mg/L Immunologic No history allergic reaction attribute compound similar chemical biologic composition study drug No ongoing active infection HIV negative Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation No psychiatric illness social situation would preclude study compliance No uncontrolled illness No malignancy within past 12 month PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior administration follow : Interferon Filgrastim ( GCSF ) , sargramostim ( GMCSF ) , epoetin alfa , hematopoietic cytokine Thalidomide thalidomide analogs No concurrent epoetin alfa Chemotherapy More 4 week since prior chemotherapy No prior arsenic trioxide azacitidine No concurrent chemotherapy Endocrine therapy More 4 week since prior steroid No concurrent androgenic steroid Concurrent steroid adrenal failure prophylaxis nausea allow Radiotherapy Not specify Surgery Not specify Other More 4 week since prior retinoids No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
</DOC>